Rain Oncology (NASDAQ:RAIN) has received an acquisition proposal from Concentra Biosciences, an affiliate of Tang Capital Partners, for $1.25/share in cash. The clinical-stage micro-cap cancer ...

The latest price target for Rain Enhancement (NASDAQ:RAIN) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $1.00 expecting RAIN to fall to within 12 months (a ...

The ionization rainfall company launched operations at its first U.S. site. The project gives Colorado its inaugural warm weather modification program at a time of persistent drought conditions across ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Rain Oncology Inc. (NASDAQ: RAIN) to Pathos AI, Inc. for $1.16 in cash per share plus a ...

Rain Oncology (NASDAQ:RAIN) has agreed to be acquired by Pathos AI for $1.16, per share in cash and a potential cash payments of up to approximately $0.17 per share. Based in Newark, California the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

The dividend was previously approved as a special stock dividend (the "Distribution") to Green Rain Energy Holdings stockholders, entitling them to one share of restricted common stock for every 100 ...